阿帕替尼治疗晚期难治性乳腺癌的临床疗效观察

Clinical Observation of Apatinib in Treatment of Refractory Advanced Breast Cancer

目的探讨阿帕替尼治疗晚期难治性乳腺癌的临床疗效及安全性。方法回顾性分析经多线治疗失败的晚期难治性乳腺癌患者29例,给予患者阿帕替尼500 mg/d,餐后半小时口服。观察临床疗效及不良反应发生情况。当出现Ⅲ级或以上不良反应时给予对症治疗及护理,仍不缓解时暂停用药,待不良反应恢复到≤Ⅰ级,再次应用阿帕替尼,并降低剂量为250 mg/d。结果CR 0例,PR 37.9%(11/29),SD 44.8%(13/29),PD 17.2%(5/29),疾病控制率(PR+SD)82.8%(24/29)。中位无进展生存期126天。主要不良反应为继发性高血压(27.59%)、手足综合征(20.69%)、继发性蛋白尿(17.24%)、恶心乏力(13.79%)、继发性口腔黏膜炎(17.24%)及腹泻(10.34%),并且Ⅰ~Ⅱ级为主。Log rank单因素分析显示:在晚期难治性乳腺癌中Luminal B型(HER2阴性)及三阴性较HER2阳性型更能从阿帕替尼获益,mPFS分别为:267、126、33 d(P=0.057)。继发性高血压及继发性蛋白尿的患者mPFS更长。Cox回归分析显示:分子分型、继发高血压和继发性蛋白尿是阿帕替尼治疗晚期难治性乳腺癌mPFS的独立影响因素。结论阿帕替尼治疗晚期难治性Luminal B(HER2阴性)型及三阴性乳腺癌仍有较好的疾病控制率及无进展生存期,不良反应可控。

Objective To evaluate the clinical efficacy and safety of apatinib in the treatment of advanced breast cancer(ABC)patients refractory to multiline treatments.Methods We retrospectively analyzed the clinical data of 29 ABC patients after the failure of multi-line treatments.Patients were treated with apatinib 500 mg/d orally.The clinical efficacy and adverse effects were evaluated.Symptomatic treatment and nursing care were given when the adverse effects were≥gradeⅢand apatinib was suspended if not get relieved.When the adverse effects were≤gradeⅠ,apatinib was administrated with reduced dosage of 250mg/d.Results Among 29 patients,there was no case with complete remission,11(37.9%)patients with partial remission(PR),13(44.8%)cases with stable disease(SD)and 5(17.2%)patients with progressive disease(PD).The disease control rate(PR+SD)was 82.8%(24/29).The median progression-free survival time(mPFS)was 126 days.The most common adverse effects were secondary hypertension(27.59%),hand-foot syndrome(20.69%),Secondary proteinuria(17.24%),nausea and fatigue(13.79%),Secondary oral mucositis(17.24%)and diarrhea(10.24%).Most of the side effects were degreeⅠ-Ⅱ.Log-rank univariate analysis showed a mPFS of 267 days for Luminal B(HER2-)ABC patients and 126 days for triple-negative group,compared with 33 days for HER2+ABC patients(P=0.057).Patients with secondary hypertension or transient proteinuria had significantly longer mPFS than those without these adverse effects(P=0.025,P=0.058).Cox regression analysis identified molecular typing,secondary hypertension and proteinuria as the independent influence factors for mPFS of ABC patients treated with apatinib.Conclusion Apatinib has relatively high DCR and PFS in the treatment of Luminal B(HER2-)and triple-negative MBC patients,and adverse reactions could be controlled.